Aspirin™ can look back at a rich, long-standing history and exciting future. For 125 years, Aspirin™ has been empowering everyday health transformation for all. The proven role of Aspirin™ in OTC pain, inflammation, and fever management, as well as low-dose Aspirin™ Cardio for cardiovascular disease prevention, continues to make it a globally versatile and trusted brand.


“No other drug in the world has had such a fascinating and record-breaking history – a development that has not yet come to an end.”

Sir John Vane   
Nobel Prize Winner

More than 7,500 million Aspirin pills a year11 allow millions to take care of their heart and live pain- and cold symptoms-free.

125 years of empowering health transformation

1897 - Dr. Felix Hoffmann

Dr. Felix Hoffmann synthesized a chemically pure and stable form of acetylsalicylic acid (ASA), the active ingredient in Aspirin™.

1899 - Aspirin™ trademark certificate signed

Aspirin™ was registered as a trademark. It was launched on the market in powder form and dispensed to customers in small paper bags. One year later, Bayer launched the analgesic in its classic tablet form.

1915 - Aspirin Car

Aspirin™ was made available without a prescription and became a best-seller in the USA.

1949 - Guinness Book of Records

Aspirin™ was featured in the Guinness Book of Records as the best-selling pain reliever in the world.

1969 - A man on the Moon

A box of Aspirin™ flew
to the moon aboard Apollo 11.

1977 - Pen signing

A study reported that Aspirin™ can prevent ischemic stroke in appropriate patients.4 The World Health Organization (WHO) introduced its
“Essential Drug List”.

1982 - Scientists in a laboratory

John Vane received the Nobel Prize for Medicine. He discovered the anti-inflammatory properties
of Aspirin™.

1993 - Heart model

In Germany and a few other countries, Aspirin introduced Aspirin™ Protect, a low-dose Aspirin™ formulation for use by appropriate at-risk patients to prevent cardiovascular events.

1999 - Image of building

Aspirin™ took place among medical advances, such as the stethoscope and artificial heart, when it was inducted into the Smithsonian Institution’s National Museum of American History, USA.

2012 - Smiling woman

Publication in the journal Headache by Lampl et al reaffirmed the effectiveness of Aspirin™ as the first-line treatment of migraine or episodic tension-type headache.8

2014 - Image of doctor with a microscope

A new Aspirin™ product was introduced in Europe and Latin America countries. Acetylsalicylic acid microparticles were combined with sodium carbonate to help Aspirin™ dissolve more quickly, enter the bloodstream faster, and relieve pain twice as fast as previous Aspirin™ tablets.9,10

Share your story

Visit Aspirin social media channels and share the power of Aspirin in your life using the hashtag #ThePowerOfAspirin

fb iconFacebook fb iconLinkedIn fb iconYouTube


1. Who List of Essential Medications: 17th List, March, 2011. (accessed March 22, 2013).

2. Weisman S, Graham D. Evaluation of the benefits and risks of low-dose Aspirin™ in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162(19):2197–2202.

3. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin™ in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomized clinical trials. Lancet 2009; 373:1849–1860.

4. Genton E, Barnett HJ, Fields WS et al. XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy. Stroke 1977;8(1):150–175.

5. Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of Aspirin™ against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396–403.

6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of Aspirin™, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569–1581.

7. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how Aspirin™ inhibits acute inflammation. J Exp Med 2004;200(1):69–78.

8. Lampl C, Voelker M, Steiner TJ. Aspirin™ is First-Line Treatment for Migraine and Episodic Tension-Type Headache Regardless of Headache Intensity. Headache 2012;52(1):48–56.

9. Voelker M.,Hammer M., Inflammopharmacology 2012;20:225-231.

10. Cooper SA., Voelker M., Inflammopharmacology 2012;20:225-242.

11. Bayer Internal Sales Report FY 2022.